Ozempic/Wegovy (Semaglutide) Denied by Insurance
Insurance denied Ozempic or Wegovy? Learn why semaglutide denials happen for diabetes vs. obesity and how to appeal with clinical evidence.
Semaglutide is a GLP-1 receptor agonist manufactured by Novo Nordisk that has become one of the most talked-about medications in years. It is marketed under two brand names with different indications: Ozempic (approved for type 2 diabetes and cardiovascular risk reduction) and Wegovy (approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity). Despite strong clinical evidence and broad FDA approval, insurance denials for both formulations are extremely common — for very different but equally frustrating reasons.
Why Insurance Denies Ozempic and Wegovy
Weight loss drug exclusions are the primary reason Wegovy is denied. Many employer-sponsored health plans, and historically most Medicare plans, explicitly exclude coverage for medications used primarily for weight management. This exclusion exists in plan documents and applies regardless of your BMI, comorbidities, or physician recommendation. As of 2025, Medicare Part D covers Wegovy only for patients with an established cardiovascular disease history (following the FLOW and SELECT trial results), not for obesity alone. Commercially insured patients may be covered depending on their specific employer plan.
The Ozempic-vs-Wegovy confusion creates its own denial category. Some patients prescribed Ozempic for weight management (rather than type 2 diabetes) have their prescription denied because Ozempic's primary FDA approval is for type 2 diabetes, not weight loss. Insurers covering diabetes drugs but not weight loss drugs may deny an Ozempic prescription when the documented diagnosis is obesity rather than T2D.
Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization thresholds for type 2 diabetes. Even when Ozempic is prescribed appropriately for T2D, prior authorization is standard. Insurers commonly require: HbA1c above a minimum threshold (often 7.5% or higher), documented failure of at least one oral antidiabetic agent (typically metformin), BMI documentation, and evidence of an active diabetes management plan.
Step therapy requires patients to try and fail other GLP-1 agonists or insulin before a semaglutide product is approved. Some plans require prior failure of liraglutide (Victoza) or dulaglutide (Trulicity) before covering Ozempic.
Supply shortage denials occurred widely from 2023 through 2025 as demand dramatically exceeded supply. Some insurers used shortage justifications to limit coverage or require alternative agents.
How to Appeal an Ozempic Denial (Diabetes Indication)
Document your A1C and treatment history. Your appeal should include current and historical HbA1c values, a list of all diabetes medications tried, doses, durations, and reasons for discontinuation or inadequate control. If metformin was tried and failed due to gastrointestinal side effects, kidney function concerns, or inadequate glucose lowering, document this explicitly.
Establish cardiovascular risk. Ozempic is also FDA-approved to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. If you have a history of heart attack, stroke, or peripheral artery disease, your physician should emphasize this indication — as cardiovascular risk reduction is often covered even by plans with restrictive diabetes formularies.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Cite ADA treatment guidelines. The American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as preferred agents for patients with T2D who have or are at risk for cardiovascular disease, heart failure, or chronic kidney disease. Referencing these guidelines strengthens your appeal significantly.
How to Appeal a Wegovy Denial (Obesity Indication)
Establish obesity as a chronic disease. Your appeal should explicitly state that obesity is a recognized chronic disease (ICD-10 code E66) and that Wegovy is not a cosmetic drug but a medically necessary treatment for a condition associated with cardiovascular disease, type 2 diabetes, sleep apnea, and premature death.
Document BMI and comorbidities. Wegovy is approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, T2D, dyslipidemia, or obstructive sleep apnea). Your appeal should document your BMI and at least one comorbidity if applicable.
Challenge the blanket exclusion. If your plan excludes all weight loss drugs, review your plan documents carefully. Some exclusions are outdated and do not account for newer medications approved for serious obesity-related conditions. An attorney or patient advocate can sometimes identify grounds to challenge a blanket exclusion as discriminatory toward a protected class.
Patient Assistance Programs
Novo Nordisk offers Novo Nordisk Patient Assistance Program (NovoCare) for eligible uninsured or underinsured patients. Visit novocare.com or call 1-833-NOVO-411. Copay cards may also be available for commercially insured patients with coverage to reduce out-of-pocket costs.
Fight Back With ClaimBack
ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.
Fight your denial at ClaimBack →
Related Reading:
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides